This Phase 2 clinical
research study is evaluating the safety and effectiveness of a once-daily oral
investigational medicine that may improve anemia and reduce the need for red
blood cell (RBC) transfusions among some patients who are chronically
transfused. All participants enrolled in the study will receive the
investigational medication.

We are currently
enrolling individuals who meet the following criteria:*

• Are 12 to 65 years of age
• Have one of the following diagnoses:
  • SCD and receiving regular
    RBC transfusions to prevent stroke or recurrence of stroke (Cohort A)
  • Thalassemia
    and receiving regular RBC transfusions (Cohort B)
    

  • Thalassemia
    and not receiving regular RBC transfusions (Cohort C)

There
are additional eligibility requirements, which the investigator will explain to
you.